Cecilia Mascia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cecilia Mascia has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Francesca Frexia
CRS4 – Center for Advanced Studies, Research and Development in Sardinia
7 shared publications - Jörg Geiger
University of Wuerzburg
5 shared publications - Luca Pireddu
CRS4, Center for Advanced Studies, Research & Development in Sardinia, Pula, Italy
5 shared publications - Petr Holub
BBMRI-ERIC, Neue Stiftingtalstraße 2/B/6, Graz, 8010, Austria
5 shared publications - Rudolf Wittner
BBMRI-ERIC
5 shared publications - Gianluigi Zanetti
Distributed Computing Group, CRS4, Pula, Italy
4 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by IOS Press
- Vol. 336, 1302-1306
A FHIR Consent Profile for European Research Biobanks
Digital dynamic consent is a key element to improve the involvement of participants as proactive partners in research and requires the adoption of standard-based information models to support data reuse. In this work we present the HL7 FHIR Consent Profile we developed to integrate individual consent preferences on biobanked samples and relative information within the infrastructure of the the Biobanking and BioMolecular Resources European Research Infrastructure Consortium (BBMRI-ERIC). The Profile builds on the official HL7 FHIR Consent Resource and adopts the Common Condition of use Elements (CCE) terminology to express the participants’ wills. A preliminary evaluation on a minimally optimized setup suggests that using the Profile’s attributes in queries adds no significant performance overhead. The current version of the Profile is available online, together with a suite of demonstrative tools, and will be implemented for validation in the final prototype of a wider pilot of the Italian Node of BBMRI-ERIC within the Strengthening BBMRI.it Project.
- 21 May 2026
- Published by IOS Press
- Vol. 336, 1302-1306
Open AccessA FHIR Consent Profile for European Research Biobanks
Digital dynamic consent is a key element to improve the involvement of participants as proactive partners in research and requires the adoption of standard-based information models to support data reuse. In this work we present the HL7 FHIR Consent Profile we developed to integrate individual consent preferences on biobanked samples and relative information within the infrastructure of the the Biobanking and BioMolecular Resources European Research Infrastructure Consortium (BBMRI-ERIC). The Profile builds on the official HL7 FHIR Consent Resource and adopts the Common Condition of use Elements (CCE) terminology to express the participants’ wills. A preliminary evaluation on a minimally optimized setup suggests that using the Profile’s attributes in queries adds no significant performance overhead. The current version of the Profile is available online, together with a suite of demonstrative tools, and will be implemented for validation in the final prototype of a wider pilot of the Italian Node of BBMRI-ERIC within the Strengthening BBMRI.it Project.
- Open Access
- 12 March 2026
- Published by Springer Nature in Scientific Data
- Vol. 13 (1)
A comprehensive European Colorectal Cancer Cohort dataset
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. The Biobanking and Biomolecular Resources European Research Infrastructure (BBMRI-ERIC) established a CRC-Cohort with European coverage contributed by 26 biobanks from 12 countries. This retrospective, multi-center study contains structured and curated clinical data, supporting research on biomarkers for early detection, prognosis, and treatment. A phenotypical/clinical data model has been defined and individual-level data from 10,780 CRC patients have been collected at BBMRI-ERIC in the central data deposition service hosted as part of its services. The participating biobanks host additional data, which can be accessed on request and used to derive additional data. This mechanism has been used to extend the collected data with scans of histopathological slides to support research in artificial intelligence in digital pathology and with whole genome sequencing data to pilot a use case of the upcoming European Health Data Space (EHDS). Here we present the methodology, the quality assurance mechanisms, and the implementation of FAIR and FAIR-Health principles applied to build the CRC-Cohort.
- 12 March 2026
- Published by Springer Nature in Scientific Data
- Vol. 13 (1)
Open AccessA comprehensive European Colorectal Cancer Cohort dataset
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. The Biobanking and Biomolecular Resources European Research Infrastructure (BBMRI-ERIC) established a CRC-Cohort with European coverage contributed by 26 biobanks from 12 countries. This retrospective, multi-center study contains structured and curated clinical data, supporting research on biomarkers for early detection, prognosis, and treatment. A phenotypical/clinical data model has been defined and individual-level data from 10,780 CRC patients have been collected at BBMRI-ERIC in the central data deposition service hosted as part of its services. The participating biobanks host additional data, which can be accessed on request and used to derive additional data. This mechanism has been used to extend the collected data with scans of histopathological slides to support research in artificial intelligence in digital pathology and with whole genome sequencing data to pilot a use case of the upcoming European Health Data Space (EHDS). Here we present the methodology, the quality assurance mechanisms, and the implementation of FAIR and FAIR-Health principles applied to build the CRC-Cohort.
- Open Access
- 25 September 2023
- Published by Elsevier in New Biotechnology
- Vol. 78, 22-28
Provenance of specimen and data – A prerequisite for AI development in computational pathology
- 25 September 2023
- Published by Elsevier in New Biotechnology
- Vol. 78, 22-28
Open AccessProvenance of specimen and data – A prerequisite for AI development in computational pathology
- Open Access
- 18 April 2023
- Published by Wiley in Learning Health Systems
- Vol. 8 (1) , e10365
Toward a common standard for data and specimen provenance in life sciences
Open and practical exchange, dissemination, and reuse of specimens and data have become a fundamental requirement for life sciences research. The quality of the data obtained and thus the findings and knowledge derived is thus significantly influenced by the quality of the samples, the experimental methods, and the data analysis. Therefore, a comprehensive and precise documentation of the pre‐analytical conditions, the analytical procedures, and the data processing are essential to be able to assess the validity of the research results. With the increasing importance of the exchange, reuse, and sharing of data and samples, procedures are required that enable cross‐organizational documentation, traceability, and non‐repudiation. At present, this information on the provenance of samples and data is mostly either sparse, incomplete, or incoherent. Since there is no uniform framework, this information is usually only provided within the organization and not interoperably. At the same time, the collection and sharing of biological and environmental specimens increasingly require definition and documentation of benefit sharing and compliance to regulatory requirements rather than consideration of pure scientific needs. In this publication, we present an ongoing standardization effort to provide trustworthy machine‐actionable documentation of the data lineage and specimens. We would like to invite experts from the biotechnology and biomedical fields to further contribute to the standard.
- 18 April 2023
- Published by Wiley in Learning Health Systems
- Vol. 8 (1) , e10365
Open AccessToward a common standard for data and specimen provenance in life sciences
Open and practical exchange, dissemination, and reuse of specimens and data have become a fundamental requirement for life sciences research. The quality of the data obtained and thus the findings and knowledge derived is thus significantly influenced by the quality of the samples, the experimental methods, and the data analysis. Therefore, a comprehensive and precise documentation of the pre‐analytical conditions, the analytical procedures, and the data processing are essential to be able to assess the validity of the research results. With the increasing importance of the exchange, reuse, and sharing of data and samples, procedures are required that enable cross‐organizational documentation, traceability, and non‐repudiation. At present, this information on the provenance of samples and data is mostly either sparse, incomplete, or incoherent. Since there is no uniform framework, this information is usually only provided within the organization and not interoperably. At the same time, the collection and sharing of biological and environmental specimens increasingly require definition and documentation of benefit sharing and compliance to regulatory requirements rather than consideration of pure scientific needs. In this publication, we present an ongoing standardization effort to provide trustworthy machine‐actionable documentation of the data lineage and specimens. We would like to invite experts from the biotechnology and biomedical fields to further contribute to the standard.
- Open Access
- 17 August 2022
- Published by Springer Nature in Scientific Data
- Vol. 9 (1) , 1-19
Lightweight Distributed Provenance Model for Complex Real–world Environments
Provenance is information describing the lineage of an object, such as a dataset or biological material. Since these objects can be passed between organizations, each organization can document only parts of the objects life cycle. As a result, interconnection of distributed provenance parts forms distributed provenance chains. Dependant on the actual provenance content, complete provenance chains can provide traceability and contribute to reproducibility and FAIRness of research objects. In this paper, we define a lightweight provenance model based on W3C PROV that enables generation of distributed provenance chains in complex, multi-organizational environments. The application of the model is demonstrated with a use case spanning several steps of a real-world research pipeline — starting with the acquisition of a specimen, its processing and storage, histological examination, and the generation/collection of associated data (images, annotations, clinical data), ending with training an AI model for the detection of tumor in the images. The proposed model has become an open conceptual foundation of the currently developed ISO 23494 standard on provenance for biotechnology domain.
- 17 August 2022
- Published by Springer Nature in Scientific Data
- Vol. 9 (1) , 1-19
Open AccessLightweight Distributed Provenance Model for Complex Real–world Environments
Provenance is information describing the lineage of an object, such as a dataset or biological material. Since these objects can be passed between organizations, each organization can document only parts of the objects life cycle. As a result, interconnection of distributed provenance parts forms distributed provenance chains. Dependant on the actual provenance content, complete provenance chains can provide traceability and contribute to reproducibility and FAIRness of research objects. In this paper, we define a lightweight provenance model based on W3C PROV that enables generation of distributed provenance chains in complex, multi-organizational environments. The application of the model is demonstrated with a use case spanning several steps of a real-world research pipeline — starting with the acquisition of a specimen, its processing and storage, histological examination, and the generation/collection of associated data (images, annotations, clinical data), ending with training an AI model for the detection of tumor in the images. The proposed model has become an open conceptual foundation of the currently developed ISO 23494 standard on provenance for biotechnology domain.
- Open Access
- 1 January 2022
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 14, 59-70
Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade
Background: The International Society of Urological Pathology (ISUP) revised the Gleason system in 2005 and 2014. The impact of these changes on prostate cancer (PCa) prognostication remains unclear. Objective: To evaluate if the ISUP 2014 Gleason score (GS) predicts PCa death better than the pre-2005 GS, and if additional histopathological information can further improve PCa death prediction. Patients and Methods: We conducted a case–control study nested among men in the National Prostate Cancer Register of Sweden diagnosed with non-metastatic PCa 1998– 2015. We included 369 men who died from PCa (cases) and 369 men who did not (controls). Two uro-pathologists centrally re-reviewed biopsy ISUP 2014 Gleason grading, poorly formed glands, cribriform pattern, comedonecrosis, perineural invasion, intraductal, ductal and mucinous carcinoma, percentage Gleason 4, inflammation, high-grade prostatic intraepithelial neoplasia (HGPIN) and post-atrophic hyperplasia. Pre-2005 GS was back-transformed using i) information on cribriform pattern and/or poorly formed glands and ii) the diagnostic GS from the registry. Models were developed using Firth logistic regression and compared in terms of discrimination (AUC). Results: The ISUP 2014 GS (AUC = 0.808) performed better than the pre-2005 GS when back-transformed using only cribriform pattern (AUC = 0.785) or both cribriform and poorly formed glands (AUC = 0.792), but not when back-transformed using only poorly formed glands (AUC = 0.800). Similarly, the ISUP 2014 GS performed better than the diagnostic GS (AUC = 0.808 vs 0.781). Comedonecrosis (AUC = 0.811), HGPIN (AUC = 0.810) and number of cores with ? 50% cancer (AUC = 0.810) predicted PCa death independently of the ISUP 2014 GS. Conclusion: The Gleason Grading revisions have improved PCa death prediction, likely due to classifying cribriform patterns, rather than poorly formed glands, as Gleason 4. Comedonecrosis, HGPIN and number of cores with ? 50% cancer further improve PCa death discrimination slightly.
- 1 January 2022
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 14, 59-70
Open AccessPrognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade
Background: The International Society of Urological Pathology (ISUP) revised the Gleason system in 2005 and 2014. The impact of these changes on prostate cancer (PCa) prognostication remains unclear. Objective: To evaluate if the ISUP 2014 Gleason score (GS) predicts PCa death better than the pre-2005 GS, and if additional histopathological information can further improve PCa death prediction. Patients and Methods: We conducted a case–control study nested among men in the National Prostate Cancer Register of Sweden diagnosed with non-metastatic PCa 1998– 2015. We included 369 men who died from PCa (cases) and 369 men who did not (controls). Two uro-pathologists centrally re-reviewed biopsy ISUP 2014 Gleason grading, poorly formed glands, cribriform pattern, comedonecrosis, perineural invasion, intraductal, ductal and mucinous carcinoma, percentage Gleason 4, inflammation, high-grade prostatic intraepithelial neoplasia (HGPIN) and post-atrophic hyperplasia. Pre-2005 GS was back-transformed using i) information on cribriform pattern and/or poorly formed glands and ii) the diagnostic GS from the registry. Models were developed using Firth logistic regression and compared in terms of discrimination (AUC). Results: The ISUP 2014 GS (AUC = 0.808) performed better than the pre-2005 GS when back-transformed using only cribriform pattern (AUC = 0.785) or both cribriform and poorly formed glands (AUC = 0.792), but not when back-transformed using only poorly formed glands (AUC = 0.800). Similarly, the ISUP 2014 GS performed better than the diagnostic GS (AUC = 0.808 vs 0.781). Comedonecrosis (AUC = 0.811), HGPIN (AUC = 0.810) and number of cores with ? 50% cancer (AUC = 0.810) predicted PCa death independently of the ISUP 2014 GS. Conclusion: The Gleason Grading revisions have improved PCa death prediction, likely due to classifying cribriform patterns, rather than poorly formed glands, as Gleason 4. Comedonecrosis, HGPIN and number of cores with ? 50% cancer further improve PCa death discrimination slightly.
- 22 August 2021
- Published by Springer Nature
- p. C1
Correction to: ISO 23494: Biotechnology – Provenance Information Model for Biological Specimen And Data
- 22 August 2021
- Published by Springer Nature
- p. C1
Correction to: ISO 23494: Biotechnology – Provenance Information Model for Biological Specimen And Data
- 9 July 2021
- Published by Springer Nature
- p. 222-225
ISO 23494: Biotechnology – Provenance Information Model for Biological Specimen And Data
- 9 July 2021
- Published by Springer Nature
- p. 222-225
ISO 23494: Biotechnology – Provenance Information Model for Biological Specimen And Data
- Open Access
openEHR is FAIR-Enabling by Design
The FAIR Principles are a set of recommendations that aim to underpin knowledge discovery and integration by making the research outcomes Findable, Accessible, Interoperable and Reusable . These guidelines encourage the accurate recording and exchange of structured data, coupled with contextual information about their creation, expressed in domain-specific standards and machine readable formats. This paper analyses the potential support to FAIRness of the openEHR e-health standard, by theoretically assessing the compliance with each of the 15 FAIR principles of a hypothetical Clinical Data Repository (CDR) developed according to the openEHR specifications. Our study highlights how the openEHR approach, thanks to its computable semantics-oriented design, is inherently FAIR-enabling and is a promising implementation strategy for creating FAIR-compliant CDRs.
Open AccessopenEHR is FAIR-Enabling by Design
The FAIR Principles are a set of recommendations that aim to underpin knowledge discovery and integration by making the research outcomes Findable, Accessible, Interoperable and Reusable . These guidelines encourage the accurate recording and exchange of structured data, coupled with contextual information about their creation, expressed in domain-specific standards and machine readable formats. This paper analyses the potential support to FAIRness of the openEHR e-health standard, by theoretically assessing the compliance with each of the 15 FAIR principles of a hypothetical Clinical Data Repository (CDR) developed according to the openEHR specifications. Our study highlights how the openEHR approach, thanks to its computable semantics-oriented design, is inherently FAIR-enabling and is a promising implementation strategy for creating FAIR-compliant CDRs.
- Open Access
- 1 January 2020
- Published by IOS Press
- Vol. 270, 443-447
The openEHR Genomics Project
Current high-throughput sequencing technologies allow us to acquire entire genomes in a very short time and at a relatively sustainable cost, thus resulting in an increasing diffusion of genetic test capabilities, in specialized clinical laboratories and research centers. In contrast, it is still limited the impact of genomic information on clinical decisions, as an effective interpretation is a challenging task. From the technological point of view, genomic data are big in size, have a complex granular nature and strongly depend on the computational steps of the generation and processing workflows. This article introduces our work to create the openEHR Genomic Project and the set of genomic information models we developed to catch such complex structure and to preserve data provenance efficiently in a machine-readable format. The models support clinical actionability of data, by improving their quality, fostering interoperability and laying the basis for re-usability.
- 1 January 2020
- Published by IOS Press
- Vol. 270, 443-447
Open AccessThe openEHR Genomics Project
Current high-throughput sequencing technologies allow us to acquire entire genomes in a very short time and at a relatively sustainable cost, thus resulting in an increasing diffusion of genetic test capabilities, in specialized clinical laboratories and research centers. In contrast, it is still limited the impact of genomic information on clinical decisions, as an effective interpretation is a challenging task. From the technological point of view, genomic data are big in size, have a complex granular nature and strongly depend on the computational steps of the generation and processing workflows. This article introduces our work to create the openEHR Genomic Project and the set of genomic information models we developed to catch such complex structure and to preserve data provenance efficiently in a machine-readable format. The models support clinical actionability of data, by improving their quality, fostering interoperability and laying the basis for re-usability.